Price (delayed)
$4.65
Market cap
$6.79M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$18.25
Enterprise value
-$17.71M
Forte Biosciences, Inc. is a clinical stage, dermatology company developing a live biotherapeutic, FB-401, for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing in adult and
There are no recent dividends present for FBRX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.